The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.

Analyst Terence Flynn from Morgan Stanley maintained a Hold rating on Gilead Sciences (GILD – Research Report) and keeping the price ...

Morgan Stanley notes that Gilead (GILD) and Arcellx’s (ACLX) anito-cel, a BCMA-directed CAR-T therapy in development for relapsed / ...

Signaturefd LLC boosted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 12.1% in the third ...

Book lovers from across the area convened on Cote Winery in Mount Gilead on Sept. 24 to celebrate the finale of the monthlong ...

Global drug shortages underscore the pharmaceutical industry's reliance on fragile supply chains, highlighting the urgent ...

HIV Research for Prevention Conference ANALYSIS | SETHI NCUBE | The 5th HIV Research for Prevention Conference (HIVR4P 2024) ...

As groundbreaking studies continue to reshape the human immunodeficiency virus (HIV) landscape, emerging therapies and ...

Yet another therapy with FDA accelerated approval suffers a setback; Sage’s tough year continues; Sanofi drops $326 million ...

Elgin and Ridgedale are in must-win games Friday night in Week 10 if they want to make the high school football playoffs.

VML Health’s Claire Gillis asks the big question about breast cancer, focusing on medical advancements and where comms can ...

Question: My problem is that some question certain character traits of President Trump and his fitness for office. I really don’t think sitting out this election is a proper option. I read your col ...